Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $879000.0.

  • Mereo BioPharma's Accounts Payables fell 4971.4% to $879000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $879000.0, marking a year-over-year decrease of 4971.4%. This contributed to the annual value of $2.4 million for FY2024, which is 400.68% up from last year.
  • Mereo BioPharma's Accounts Payables amounted to $879000.0 in Q3 2025, which was down 4971.4% from $1.1 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Accounts Payables high stood at $3.6 million for Q2 2022, and its period low was $879000.0 during Q3 2025.
  • In the last 5 years, Mereo BioPharma's Accounts Payables had a median value of $2.6 million in 2024 and averaged $2.5 million.
  • Data for Mereo BioPharma's Accounts Payables shows a peak YoY increase of 1910.39% (in 2025) and a maximum YoY decrease of 5785.19% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Mereo BioPharma's Accounts Payables stood at $3.4 million in 2021, then increased by 3.66% to $3.5 million in 2022, then tumbled by 32.82% to $2.3 million in 2023, then grew by 4.01% to $2.4 million in 2024, then crashed by 63.98% to $879000.0 in 2025.
  • Its Accounts Payables stands at $879000.0 for Q3 2025, versus $1.1 million for Q2 2025 and $2.9 million for Q1 2025.